Medicine
Constulose 10 g/15 mL oral solution
Constulose 10 g/15 mL oral solution is a prescription medicine containing Lactulose for oral use, marketed by Actavis Pharma, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Do not freeze. Prolonged exposure to freezing temperatures may cause change to…
Key facts
- Active ingredient (INN)
- Lactulose
- Brand
- Constulose
- Strength
- 10 g/15 mL
- Dosage form
- Oral solution
- Route
- Oral
- Packs
- 237 mL, 946 mL
- Marketing authorisation holder
- Actavis Pharma
- Manufacturer
- Actavis Pharma
- Origin register
- US FDA, United States
- Storage
- Do not freeze. Prolonged exposure to freezing temperatures may cause change to a semi-solid, too viscous to pour. Store between 36° to 86°F (2° to 30°C). Prolonged exposure to temperatures above 86°F (30°C) or to direct light may cause extreme darkening and turbidity which may be pharmaceutically objectionable. Viscosity will return to normal upon warming to room temperature.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- A06AD11 Lactulose
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 28 February 2011
- Identifiers
- RxCUI 391937, 544452DailyMed set ID 461ec39f-eeb4-4460-9b5c-62367d47162bNDC 45963-439Application ANDA090503
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 237 mL in 1 bottle | 45963-439-63 | Actavis Pharma | 28 February 2011 |
| 946 mL in 1 bottle | 45963-439-65 | Actavis Pharma | 28 February 2011 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 25 March 1976 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Lactulose 10 g/15 mL oral solution.
Other strengths and forms of Lactulose
Clinical summary
Lactulose is an osmotic laxative indicated for the treatment of constipation. It is available as oral solution and powder for oral solution for rectal use. MedsAcross supplies Lactulose for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about LactuloseFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Lactulose prescribing information (Foxland Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Constulose 10 g/15 mL oral solution for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.